Companies › Tr1X
2 active drug programs in 4 registered trials: 4 Phase 1; Immunology, Infectious disease, Oncology, Neurology; next expected readout Jan 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| TRX103 Investigational biological therapy for Crohn's Disease | – | Phase 1 | Crohns Disease; Hematologic Malignancy; Non Infectious Uveitis | Jan 2027 |
| TRX319 Cell therapy | – | Phase 1 | Primary Progressive Multiple Sclerosis | Aug 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06721962 | TRX103 | Phase 1 | Crohns Disease | Immunology | Jan 2027 |
| NCT06462365 | TRX103 | Phase 1 | Hematologic Malignancy | Oncology | Apr 2027 |
| NCT07477639 | TRX319 | Phase 1 | Primary Progressive Multiple Sclerosis | Neurology | Aug 2028 |
| NCT07427628 | TRX103 | Phase 1 | Non Infectious Uveitis | Infectious disease | Dec 2028 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.